Biodyne바이오다인
314930 · KOSDAQ · ₩314930 · 바이오다인
- Market cap
- ₩175B
- Enterprise value
- ₩161B
- P/E
- 222.5×
- P/B
- 4.0×
- Dividend yield
- 0.0%
- ROE
- 1.8%
- Net margin
- 13.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−65.1% from the high
₩5,210Today: ₩5,500 – ₩6,080₩16,860
Returns
- 1W−1.7%
- 1M−12.4%
- 3M−28.6%
- 6M−49.5%
- YTD−56.4%
- 1Y−56.8%
- Volume today
- 63,595
- 2.2× the 20-day average
- Traded today
- ₩363M
- Listed shares
- 29,764,103
- EPS (12 months)
- ₩26
- Earnings yield 0.4%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 56: heavy trading.
- MomentumWeak-10.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Biodyne stock overview
Biodyne (바이오다인, KRX: 314930) is listed on KOSDAQ, in the Medical & precision devices sector. This Korean company develops, manufactures and sells liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis, centered on its patented blowing technology. Its shares closed at ₩5,890 on Oct 30, 2026, up 2.08% on the day, giving it a market value of ₩175B.
Key facts
- Market cap
- ₩175B
- Sector
- Medical & precision devices
- Latest price change
- +2.08%
- As of
- Oct 30, 2026
- Main business
- This Korean company develops, manufactures and sells liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis, centered on its patented blowing technology.
Quick answers about Biodyne
- What does Biodyne do?
- This Korean company develops, manufactures and sells liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis, centered on its patented blowing technology. Its main products include the PATHPLORER automated LBC systems and PATHPLORER-brand kits with cell preservation solutions, membrane filters, vials, slides and brushes, with cervical cancer testing being the largest application. The company has licensed its slide-preparation technology to Roche and exports to 13 countries, including Japan, Russia, Portugal and Thailand.
- What is the market cap of Biodyne?
- The market capitalisation of Biodyne was ₩175B at the close on Oct 30, 2026.
- Who are the largest shareholders of Biodyne?
- According to the latest official filings, the largest reported holders are Im Wook-bin (42.21%, as of Aug 14, 2026); National Pension Service (0.37%, as of Dec 31, 2024); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.25%, as of Jul 31, 2026).
- When is the next earnings report from Biodyne?
- Korean companies rarely announce results dates in advance. Based on when Biodyne filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Biodyne?
- Yes. The National Pension Service held 0.37% of Biodyne shares as of Dec 31, 2024.
Company profile
This Korean company develops, manufactures and sells liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis, centered on its patented blowing technology. Its main products include the PATHPLORER automated LBC systems and PATHPLORER-brand kits with cell preservation solutions, membrane filters, vials, slides and brushes, with cervical cancer testing being the largest application. The company has licensed its slide-preparation technology to Roche and exports to 13 countries, including Japan, Russia, Portugal and Thailand.
Written by AI from the company's latest annual report.
- Korean name
- 바이오다인
- Themes
- Medical devices
- CEO
- 임욱빈
- Founded
- Oct 1999
- Listed
- Mar 2021
- Listed shares
- 29,764,103
- Fiscal year ends
- Month 12
- Website
- www.biodyne.asia/
Similar companies
- TSE131290 · ₩2.5T₩222,000−14.78%
- Kctech281820 · ₩1.7T₩87,500−10.26%
- Classys214150 · ₩1.7T₩26,200−2.24%
- Park Systems140860 · ₩1.5T₩219,500−3.94%
- DI003160 · ₩1.1T₩39,000−10.34%
- LivsMed491000 · ₩995B₩39,400−2.60%
- Seers458870 · ₩859B₩22,400−5.29%
- Curiox Biosystems445680 · ₩851B₩49,400−18.48%
Recent filings
See all- Amended: Half-year report (Jun 2026)Oct 12, 2026
- 5%+ holding reportAug 14, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- Decision on Loan Provision (Voluntary Disclosure)Aug 3, 2026
- Insider shareholding reportJul 13, 2026
Titles in Korean until English translations are added.
Also known as: Biodyne / 바이오다인 / 314930 / KRX:314930
Source: KRX statistical information